Opdualag for Metastatic Melanoma
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668g ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Opdualag (BMS), a fixed-dose combination of two immune checkpoint inhibitors — nivolumab (Opdivo), a programmed death receptor-1 (PD-1) inhibitor, and relatlimab-rmbw, a lymphocyte-activation gene-3 (LAG-3) blocking antibody — has been approved by the FDA for treatment of unresectable or metastatic melanoma in patients ≥12 years old.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Opdualag for Metastatic Melanoma. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668g
Vancouver
Opdualag for Metastatic Melanoma. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668g
BibTeX
@article{euvimed2023,
title = {Opdualag for Metastatic Melanoma},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668g}
}
EUVIMED